RTP-026 / ResoTher Pharma - LARVOL DELTA

Research Progress of Annexin A1 and Its Derived Peptides in the Diagnosis and Treatment of Circulatory Diseases. (PubMed, Immun Inflamm Dis) - "ANXA1 represents a promising diagnostic biomarker and therapeutic target for circulatory diseases. Further research is needed to elucidate its complex regulatory networks and validate its clinical applicability through multi-omics approaches and large-scale trials."

Journal • Review • Cardiovascular • CNS Disorders • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hypertension • Immune Modulation • Immunology • Infectious Disease • Inflammation • Myocardial Ischemia • Reperfusion Injury • Septic Shock • Vascular Neurology • AMPK • ANXA1 • SIRT3

Pro-resolving lipid mediators and therapeutic innovations in resolution of inflammation. (PubMed, Pharmacol Ther) - "In addition to SPMs, we highlight the discovery, biosynthesis, biofunctions, and latest research updates on innovative therapeutics (including annexin-A1 peptide-mimetic RTP-026, small molecule FPR2 agonist BM-986235/LAR-1219, biased agonist for FPR1/FPR2 Cmpd17b, lipoxin mimetics AT-01-KG and AT-02-CT, melanocortin receptor agonist AP1189, gold nanoparticles, angiotensin-(1-7), and CD300a) that can promote resolution of inflammation directly or through modulation of SPMs production. Drug development strategies based on the biology of the resolution of inflammation can offer novel therapeutic means and/or add-on therapies for the treatment of chronic diseases."

Journal • Review • Allergy • Cardiovascular • Immunology • Infectious Disease • Inflammation • Rheumatology • ANXA1

An Exploratory, Randomised, Double-blind Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI) (clinicaltrials.gov) - P2 | N=96 | Recruiting | Sponsor: ResoTher Pharma

New P2 trial • Cardiovascular • Myocardial Infarction